Johnson & Johnson has announced plans to open four innovation centers in California, Boston, London, and China, with the aim of accelerating early innovation and facilitating collaboration and investment opportunities.
Johnson & Johnson (J&J) has announced plans to open four innovation centers in California, Boston, London, and China, with the aim of accelerating early innovation and facilitating collaboration and investment opportunities. The company is aiming to have the centers operational within the coming months.
According to a press statement, the areas chosen for the centers are “innovation hotspots.” Each center will serve as a regional hub and will possess science and technology experts, as well as local deal-making capabilities. The centers will be looking to identify promising early stage innovations and to establish collaborations to further explore their development potential for unmet medical needs.
"Today, leading innovation sources have concentrated geographic presence in selected locations around the world," Diego Miralles, MD, head of the California innovation center, said in the J&J statement. "By refocusing our outward facing activities and locating our experts and our deal-making capabilities in those regional hubs we can simplify the deal making and coordination for entrepreneurs who are looking to collaborate and partner with the Johnson & Johnson family of companies."
The centers will provide scientists, entrepreneurs and emerging companies researching early-stage opportunities with access to experts at J&J, who will then facilitate collaboration across J&J’s pharmaceutical, medical device and diagnostics, and consumer businesses. According to the press statement, J&J has a history of accessing early innovation through its Corporate Office of Science and Technology, J&J Development Corporation and RedScript Ventures, as well as other efforts in its business sectors. The new innovation centers will coordinate all early stage efforts into four hubs. Later licensing and acquisition opportunities will continue to be managed by J&J’s Business Development team.
"The innovation centers will help to deepen our relationships with the communities in key innovation hotspots and better support local entrepreneurs," Patrick Verheyen, head of the London innovation center, said in the J&J statement. "Ultimately they will serve to help us more quickly identify and tap into technological advancements that have the potential to benefit the health of people in the future."
Drug Shortages and Complying with FDA’s 21 CFR 211.110 Guidance
April 2nd 2025Susan J. Schniepp, distinguished fellow at Regulatory Compliance Associates, and Rona LeBlanc-Rivera, PhD, principal consultant, Regulatory Affairs at Regulatory Compliance Associates, answer some questions about FDA’s January 2025 21 CFR 211.110 guidance document.
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
November 14th 2023In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.